પ્રોસ્ટેટ કેન્સર

Aim of the study to improve the treatment of high-risk non-metastatic prostate cancer by comparing reduced duration of hormone therapy to the standard duration of two years, when combined with curative intent standard of care radiotherapy to prostate and pelvic nodes. The reduced duration will be intensified with addition of newer hormonal agents such as abiraterone or enzalutamide tablets, which have been shown to improve disease control in locally advanced prostate cancer. This is hoped to reduce the side effects of prolonged hormone therapy, while maintaining similar rates of disease contro…

Sponsor: Tata Memorial Centre
NCT06818682 on ClinicalTrials.gov
છેલ્લે 21 Feb 2025 ના રોજ registry માં update થયું · અમને 20 Oct 2026 ના રોજ વાંચ્યું